ATE377426T1 - Therapeutische verwendung eines rekombinanten erythropoietins omega mit hoher aktivität und verminderten nebenwirkungen - Google Patents

Therapeutische verwendung eines rekombinanten erythropoietins omega mit hoher aktivität und verminderten nebenwirkungen

Info

Publication number: ATE377426T1
Authority: AT; Austria
Prior art keywords: treatment; novel; recombinant; pain; side effects
Prior art date: 2000-08-11

Application number

AT01971896T

Other languages

English (en)

Inventor

Lawrence Thompson

Original Assignee

Baxter Healthcare Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-11

Filing date

2001-08-09

Publication date

2007-11-15

2001-08-09 Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa

2007-11-15 Application granted granted Critical

2007-11-15 Publication of ATE377426T1 publication Critical patent/ATE377426T1/de

Links

108090000394 Erythropoietin Proteins 0.000 title abstract 4
102000003951 Erythropoietin Human genes 0.000 title abstract 4
229940105423 erythropoietin Drugs 0.000 title abstract 4
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 4
230000000694 effects Effects 0.000 title abstract 3
230000001225 therapeutic effect Effects 0.000 title abstract 3
238000011282 treatment Methods 0.000 abstract 6
206010020772 Hypertension Diseases 0.000 abstract 3
208000007536 Thrombosis Diseases 0.000 abstract 2
230000002411 adverse Effects 0.000 abstract 2
208000007502 anemia Diseases 0.000 abstract 2
108010090921 epoetin omega Proteins 0.000 abstract 2
229950008767 epoetin omega Drugs 0.000 abstract 2
241000699800 Cricetinae Species 0.000 abstract 1
241000699802 Cricetulus griseus Species 0.000 abstract 1
108010074604 Epoetin Alfa Proteins 0.000 abstract 1
206010028813 Nausea Diseases 0.000 abstract 1
206010047095 Vascular pain Diseases 0.000 abstract 1
238000002512 chemotherapy Methods 0.000 abstract 1
239000002299 complementary DNA Substances 0.000 abstract 1
229960003388 epoetin alfa Drugs 0.000 abstract 1
108010002601 epoetin beta Proteins 0.000 abstract 1
229960004579 epoetin beta Drugs 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
238000002347 injection Methods 0.000 abstract 1
239000007924 injection Substances 0.000 abstract 1
210000003292 kidney cell Anatomy 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000008693 nausea Effects 0.000 abstract 1
210000001672 ovary Anatomy 0.000 abstract 1
238000001959 radiotherapy Methods 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Diabetes (AREA)
Hematology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

AT01971896T 2000-08-11 2001-08-09 Therapeutische verwendung eines rekombinanten erythropoietins omega mit hoher aktivität und verminderten nebenwirkungen ATE377426T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/637,962 US7078376B1 (en)	2000-08-11	2000-08-11	Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects

Publications (1)

Publication Number	Publication Date
ATE377426T1 true ATE377426T1 (de)	2007-11-15

Family

ID=24558080

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT07075711T ATE555802T1 (de)	2000-08-11	2001-08-09	Therapeutische verwendung von erythropoietin omega
AT01971896T ATE377426T1 (de)	2000-08-11	2001-08-09	Therapeutische verwendung eines rekombinanten erythropoietins omega mit hoher aktivität und verminderten nebenwirkungen

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT07075711T ATE555802T1 (de)	2000-08-11	2001-08-09	Therapeutische verwendung von erythropoietin omega

Country Status (18)

Country	Link
US (1)	US7078376B1 (de)
EP (2)	EP1317276B1 (de)
JP (1)	JP5105687B2 (de)
KR (2)	KR100887463B1 (de)
CN (1)	CN100558744C (de)
AT (2)	ATE555802T1 (de)
AU (3)	AU2001291755B2 (de)
BR (1)	BRPI0113189B1 (de)
CA (2)	CA2418531C (de)
CZ (1)	CZ304572B6 (de)
DE (1)	DE60131286T2 (de)
HU (1)	HUP0300740A3 (de)
IL (3)	IL154170A0 (de)
MX (1)	MXPA03001237A (de)
NZ (2)	NZ524000A (de)
PL (1)	PL364248A1 (de)
RU (1)	RU2282460C2 (de)
WO (1)	WO2002014356A2 (de)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1329119C (en) *	1988-03-29	1994-05-03	Milton David Goldenberg	Cytotoxic therapy
US20030232010A2 (en) *	1988-03-29	2003-12-18	Immunomedics, Inc.	Improved cytotoxic therapy
DE10234192B4 (de) *	2002-07-26	2009-11-26	Epoplus Gmbh Co.Kg	Verwendung von Erythropoetin
US7459436B2 (en) *	2002-11-22	2008-12-02	Hoffmann-La Roche Inc.	Treatment of disturbances of iron distribution
US7388079B2 (en) *	2002-11-27	2008-06-17	The Regents Of The University Of California	Delivery of pharmaceutical agents via the human insulin receptor
US7141544B2 (en) *	2003-10-10	2006-11-28	Baxter International, Inc.	Stabilization of pharmaceutical protein formulations with small peptides
DE102004004509B4 (de) *	2004-01-23	2010-07-01	Epoplus Gmbh Co.Kg	Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
UA89630C2 (ru) *	2004-03-26	2010-02-25	Янссен Фармацевтика Н.В.	Схема комбинированного дозирования для эритропоэтина
US20050255112A1 (en) *	2004-05-17	2005-11-17	Lee Jong Y	Compositions and methods for preventing erythropoietin-associated hypertension
US20070037886A1 (en) *	2005-04-26	2007-02-15	Ajinomoto Co., Inc.	Bone marrow erythroid progenitor cell(s) differentiation inducer
US8124095B2 (en)	2005-10-07	2012-02-28	Armagen Technologies, Inc.	Fusion proteins for delivery of erythropoietin to the CNS
US8053569B2 (en) *	2005-10-07	2011-11-08	Armagen Technologies, Inc.	Nucleic acids encoding and methods of producing fusion proteins
US8741260B2 (en)	2005-10-07	2014-06-03	Armagen Technologies, Inc.	Fusion proteins for delivery of GDNF to the CNS
US8759297B2 (en) *	2006-08-18	2014-06-24	Armagen Technologies, Inc.	Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
US20080064702A1 (en) *	2006-09-08	2008-03-13	Charalambos Antoniades	Use of folates for the prevention and treatment of vascular diseases
WO2008137066A1 (en) *	2007-05-02	2008-11-13	The Board Of Regents Of The University Of Oklahoma	Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
RU2344830C1 (ru) *	2007-05-22	2009-01-27	Государственное образовательное учреждение высшего профессионального образования Новосибирский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию (ГОУ ВПО НГМУ Росздрава)	Способ определения чувствительности больного с анемией хронических заболеваний к терапии анемического синдрома препаратами рекомбинантного человеческого эритропоэтина
AU2008282496B2 (en)	2007-07-27	2013-04-04	Armagen Technologies, Inc.	Methods and compositions for increasing alpha-iduronidase activity in the CNS
EP2205280B1 (de)	2007-09-27	2019-09-04	Amgen Inc.	Pharmazeutische formulierungen
US8796206B2 (en)	2007-11-15	2014-08-05	Amgen Inc.	Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
WO2009089039A1 (en) *	2008-01-09	2009-07-16	Cho Daniel J	Use of blood flow parameters to monitor or control the dosing of erythropoiesis-stimulating agents
WO2009094551A1 (en)	2008-01-25	2009-07-30	Amgen Inc.	Ferroportin antibodies and methods of use
US9315577B2 (en)	2008-05-01	2016-04-19	Amgen Inc.	Anti-hepcidin antibodies and methods of use
JP6018753B2 (ja)	2008-11-13	2016-11-02	ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅＧｅｎｅｒａｌＨｏｓｐｉｔａｌＣｏｒｐｏｒａｔｉｏｎ	Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
CA2748889A1 (en)	2009-03-18	2010-09-23	Armagen Technologies, Inc.	Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
EP2485761B1 (de)	2009-10-09	2019-02-27	Armagen, Inc.	Verfahren und zusammensetzungen für erhöhte iduronat-2-sulfatase-aktivität im zns
WO2011050333A1 (en)	2009-10-23	2011-04-28	Amgen Inc.	Vial adapter and system
SG186094A1 (en)	2010-06-07	2013-01-30	Amgen Inc	Drug delivery device
US20120016686A1 (en) *	2010-07-13	2012-01-19	Cerner Innovation, Inc.	Inpatient blood management
ES2388395B1 (es) *	2011-03-18	2013-10-01	Dr Healthcare España, S. L.	Uso de la diaminooxidasa para el tratamiento o la prevención de la fibromialgia o la fatiga crónica.
AU2012236573B2 (en)	2011-03-31	2016-06-02	Amgen Inc.	Vial adapter and system
HUE042822T2 (hu)	2011-04-20	2019-07-29	Amgen Inc	Automata befecskendezõ szerkezet
PL3045187T3 (pl)	2011-10-14	2019-09-30	Amgen Inc.	Wstrzykiwacz i sposób montażu
AU2012346448B2 (en)	2011-12-02	2017-09-14	Armagen, Inc.	Methods and compositions for increasing arylsulfatase A activity in the CNS
ES2860954T3 (es)	2012-11-21	2021-10-05	Amgen Inc	Dispositivo de administración de fármacos
JP6336564B2 (ja)	2013-03-15	2018-06-06	アムゲン・インコーポレーテッド	薬物カセット、自動注入器、および自動注入器システム
US10646664B2 (en)	2013-03-15	2020-05-12	Amgen Inc.	Body contour adaptable autoinjector device
TWI614041B (zh)	2013-03-15	2018-02-11	安美基公司	用於注射器之匣盒
WO2014152006A2 (en)	2013-03-15	2014-09-25	Intrinsic Lifesciences, Llc	Anti-hepcidin antibodies and uses thereof
WO2014149357A1 (en)	2013-03-22	2014-09-25	Amgen Inc.	Injector and method of assembly
CA3168888A1 (en)	2013-10-24	2015-04-30	Amgen Inc.	Drug delivery system with temperature-sensitive control
SG11201602876WA (en)	2013-10-24	2016-05-30	Amgen Inc	Injector and method of assembly
US10994112B2 (en)	2014-02-05	2021-05-04	Amgen Inc.	Drug delivery system with electromagnetic field generator
AU2015256082C1 (en)	2014-05-07	2020-09-10	Amgen Inc.	Autoinjector with shock reducing elements
CN111840696B (zh)	2014-06-03	2022-12-20	安姆根有限公司	可控制药物递送系统和使用方法
US10323088B2 (en)	2014-09-22	2019-06-18	Intrinsic Lifesciences Llc	Humanized anti-hepcidin antibodies and uses thereof
EP3206739B1 (de)	2014-10-14	2021-12-01	Amgen Inc.	Vorrichtung zur injektion von medikamenten mit visuellen indikatoren und audio-indikatoren
MA40904A (fr) *	2014-11-03	2017-09-12	Hygeia Tech Inc	Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie
US11357916B2 (en)	2014-12-19	2022-06-14	Amgen Inc.	Drug delivery device with live button or user interface field
EP3848072A1 (de)	2014-12-19	2021-07-14	Amgen Inc.	Medikamentenabgabevorrichtung mit näherungssensor
US10538589B2 (en)	2015-01-14	2020-01-21	Armagen Inc.	Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
JP6484345B2 (ja)	2015-02-17	2019-03-20	アムジエン・インコーポレーテツド	固定及び／または戻りが真空によって支援された薬物送達装置
WO2016138434A1 (en)	2015-02-27	2016-09-01	Amgen Inc.	Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
PE20180690A1 (es)	2015-04-27	2018-04-23	Intercept Pharmaceuticals Inc	Composiciones de acido obeticolico y metodos de uso
WO2017039786A1 (en)	2015-09-02	2017-03-09	Amgen Inc.	Syringe assembly adapter for a syringe
JP7082568B2 (ja)	2015-12-09	2022-06-08	アムジエン・インコーポレーテツド	信号伝達キャップ付き自動注射器
US11154661B2 (en)	2016-01-06	2021-10-26	Amgen Inc.	Auto-injector with signaling electronics
DK3429663T3 (da)	2016-03-15	2020-09-28	Amgen Inc	Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
WO2017189089A1 (en)	2016-04-29	2017-11-02	Amgen Inc.	Drug delivery device with messaging label
US11389588B2 (en)	2016-05-02	2022-07-19	Amgen Inc.	Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en)	2016-05-13	2022-12-22	Amgen Inc.	Vial sleeve assembly
WO2017200989A1 (en)	2016-05-16	2017-11-23	Amgen Inc.	Data encryption in medical devices with limited computational capability
US11541176B2 (en)	2016-06-03	2023-01-03	Amgen Inc.	Impact testing apparatuses and methods for drug delivery devices
EP3478342B1 (de)	2016-07-01	2025-03-12	Amgen Inc.	Arzneimittelabgabevorrichtung mit minimiertem teilebruchrisiko nach aufprallereignissen
WO2018034784A1 (en)	2016-08-17	2018-02-22	Amgen Inc.	Drug delivery device with placement detection
US20200261643A1 (en)	2016-10-25	2020-08-20	Amgen Inc.	On-body injector
AU2018210301A1 (en)	2017-01-17	2019-08-01	Amgen Inc.	Injection devices and related methods of use and assembly
WO2018151890A1 (en)	2017-02-17	2018-08-23	Amgen Inc.	Drug delivery device with sterile fluid flowpath and related method of assembly
CA3052204A1 (en)	2017-02-17	2018-08-23	Amgen Inc.	Insertion mechanism for drug delivery device
EP3592403B1 (de)	2017-03-06	2025-08-20	Amgen Inc.	Wirkstofffreisetzungsvorrichtung mit aktivierungsverhinderungsfunktion
US11571511B2 (en)	2017-03-07	2023-02-07	Amgen Inc.	Insertion mechanism and method of inserting a needle of a drug delivery device
AU2018230486B2 (en)	2017-03-09	2023-05-11	Amgen Inc.	Insertion mechanism for drug delivery device
EP3570871B1 (de)	2017-03-20	2020-11-18	H. Hoffnabb-La Roche Ag	Verfahren für in-vitro-glyco-engineering eines erythropoiesestimulierenden proteins
ES3023742T3 (en)	2017-03-28	2025-06-03	Amgen Inc	Plunger rod and syringe assembly system
US11590294B2 (en)	2017-06-08	2023-02-28	Amgen Inc.	Syringe assembly for a drug delivery device and method of assembly
JP7200134B2 (ja)	2017-06-08	2023-01-06	アムジエン・インコーポレーテツド	トルク駆動式薬物送達デバイス
JP7195276B2 (ja)	2017-06-22	2022-12-23	アムジエン・インコーポレーテツド	デバイス起動による衝突／衝撃の低減
WO2018237225A1 (en)	2017-06-23	2018-12-27	Amgen Inc.	Electronic drug delivery device comprising a cap activated by a switch assembly
IL270784B2 (en)	2017-07-14	2023-11-01	Amgen Inc	Needle insertion-extraction system with a double torsion spring system
JP7649105B2 (ja)	2017-07-21	2025-03-19	アムジエン・インコーポレーテツド	薬物容器のためのガス透過性シーリング部材及び組立方法
MA49676A (fr)	2017-07-25	2020-06-03	Amgen Inc	Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
US11617837B2 (en)	2017-07-25	2023-04-04	Amgen Inc.	Drug delivery device with gear module and related method of assembly
MA49838A (fr)	2017-08-09	2020-06-17	Amgen Inc	Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
EP3668567B1 (de)	2017-08-18	2026-02-18	Amgen Inc.	Tragbarer injektor mit sterilem klebepatch
US11103636B2 (en)	2017-08-22	2021-08-31	Amgen Inc.	Needle insertion mechanism for drug delivery device
WO2019070472A1 (en)	2017-10-04	2019-04-11	Amgen Inc.	FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
ES2971450T3 (es)	2017-10-06	2024-06-05	Amgen Inc	Dispositivo de administración de fármacos con conjunto de enclavamiento y procedimiento de montaje correspondiente
US11464903B2 (en)	2017-10-09	2022-10-11	Amgen Inc.	Drug delivery device with drive assembly and related method of assembly
IL273582B2 (en)	2017-11-03	2024-12-01	Amgen Inc	Systems and approaches for sterilizing a drug delivery device
EP3707075A1 (de)	2017-11-06	2020-09-16	Amgen Inc.	Füllabschlussanordnungen und zugehörige verfahren
EP3706830B1 (de)	2017-11-06	2024-08-07	Amgen Inc.	Arzneimittelabgabevorrichtung mit positionierungs- und durchflussmessung
MA50557A (fr)	2017-11-10	2020-09-16	Amgen Inc	Pistons pour dispositifs d'administration de médicament
MX2020005066A (es)	2017-11-16	2020-08-20	Amgen Inc	Autoinyector con deteccion de detencion y punto final.
JP7370969B2 (ja)	2017-11-16	2023-10-30	アムジエン・インコーポレーテツド	薬物送達デバイスの扉ラッチ機構
US10835685B2 (en)	2018-05-30	2020-11-17	Amgen Inc.	Thermal spring release mechanism for a drug delivery device
US11083840B2 (en)	2018-06-01	2021-08-10	Amgen Inc.	Modular fluid path assemblies for drug delivery devices
CA3103681A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Delivery devices for administering drugs
MA53375A (fr)	2018-07-24	2021-06-02	Amgen Inc	Dispositifs d'administration pour l'administration de médicaments
US12303677B2 (en)	2018-07-24	2025-05-20	Amgen Inc.	Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023336A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with grip portion
CA3103105A1 (en)	2018-07-31	2020-02-06	Amgen Inc.	Fluid path assembly for a drug delivery device
US20210346601A1 (en)	2018-09-24	2021-11-11	Amgen Inc.	Interventional dosing systems and methods
CA3110371A1 (en)	2018-09-28	2020-04-02	Amgen Inc.	Muscle wire escapement activation assembly for a drug delivery device
EP3860685A1 (de)	2018-10-02	2021-08-11	Amgen Inc.	Injektionssysteme zur wirkstoffabgabe mit übertragung der inneren kraft
US12151089B2 (en)	2018-10-05	2024-11-26	Amgen Inc.	Drug delivery device having dose indicator
WO2020081480A1 (en)	2018-10-15	2020-04-23	Amgen Inc.	Platform assembly process for drug delivery device
TW202541859A (zh)	2018-10-15	2025-11-01	美商安進公司	具有阻尼機構之藥物遞送裝置及自動注射器
MA54048A (fr)	2018-11-01	2022-02-09	Amgen Inc	Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
EP3873563A1 (de)	2018-11-01	2021-09-08	Amgen Inc.	Vorrichtung zur verabreichung von medikamenten mit partiellem einzug des wirkstoffabgabeelements
TWI831847B (zh)	2018-11-01	2024-02-11	美商安進公司	部分針頭縮回之藥物遞送裝置及其操作方法
AU2020263289B2 (en)	2019-04-24	2025-05-22	Amgen Inc.	Syringe sterilization verification assemblies and methods
WO2021041067A2 (en)	2019-08-23	2021-03-04	Amgen Inc.	Drug delivery device with configurable needle shield engagement components and related methods
CU24704B1 (es) *	2019-09-05	2024-04-08	Ct Inmunologia Molecular	Método para la obtención de eritropoyetina humana recombinante hiposialilada para el tratamiento de alteraciones del sistema nervioso
RU2736206C1 (ru) *	2020-02-10	2020-11-12	Федеральное государственное бюджетное образовательное учреждение высшего образования "Ярославский государственный медицинский университет" Министерства здравоохранения Российской Федерации	Способ прогнозирования риска формирования тромбоза постоянного сосудистого доступа в период от 6 месяцев до 1 года у пациентов, находящихся на программном гемодиализе
JP2024523779A (ja)	2021-05-21	2024-07-02	アムジェンインコーポレイテッド	薬物容器用の充填レシピを最適化する方法
WO2024094457A1 (en)	2022-11-02	2024-05-10	F. Hoffmann-La Roche Ag	Method for producing glycoprotein compositions
WO2026030152A1 (en)	2024-07-29	2026-02-05	Amgen Inc.	System and method for assessing transferability of a fill recipe

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR850004274A (ko)	1983-12-13	1985-07-11	원본미기재	에리트로포이에틴의 제조방법
US4703008A (en)	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
CN1224726A (zh) *	1986-06-27	1999-08-04	华盛顿大学评议会	人红血球生成素基因在稳定转染的哺乳动物细胞中的高水平表达
DK173067B1 (da)	1986-06-27	1999-12-13	Univ Washington	Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US5661125A (en) *	1992-08-06	1997-08-26	Amgen, Inc.	Stable and preserved erythropoietin compositions
ZA975264B (en)	1996-06-17	1997-12-17	Smithkline Beecham Corp	Method for treating congestive heart failure.
RU2128517C1 (ru) *	1998-07-20	1999-04-10	Колобков Сергей Леонидович	Стабилизированный водный раствор эритропоэтина
AU774989B2 (en)	1998-10-23	2004-07-15	Amgen, Inc.	Methods and compositions for the prevention and treatment of anemia
DE19857609A1 (de)	1998-12-14	2000-06-15	Hannelore Ehrenreich	Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
AU2001254625B2 (en)	2000-05-02	2006-02-02	Action Pharma A/S	Use of alpha-MSH and EPO for preventing or treating ischemic conditions
US20020037832A1 (en)	2000-05-02	2002-03-28	Soren Nielsen	Use of alpha-MSH and EPO for preventing or treating ischemic conditions
CN1318084C (zh)	2000-05-26	2007-05-30	奥索-麦克尼尔药品公司	神经保护肽

2000
- 2000-08-11 US US09/637,962 patent/US7078376B1/en not_active Expired - Lifetime
2001
- 2001-08-09 EP EP01971896A patent/EP1317276B1/de not_active Expired - Lifetime
- 2001-08-09 KR KR1020037001938A patent/KR100887463B1/ko not_active Expired - Fee Related
- 2001-08-09 AU AU2001291755A patent/AU2001291755B2/en not_active Ceased
- 2001-08-09 BR BRPI0113189-3A patent/BRPI0113189B1/pt not_active IP Right Cessation
- 2001-08-09 DE DE60131286T patent/DE60131286T2/de not_active Expired - Lifetime
- 2001-08-09 HU HU0300740A patent/HUP0300740A3/hu unknown
- 2001-08-09 PL PL01364248A patent/PL364248A1/xx not_active IP Right Cessation
- 2001-08-09 WO PCT/EP2001/009209 patent/WO2002014356A2/de not_active Ceased
- 2001-08-09 IL IL15417001A patent/IL154170A0/xx unknown
- 2001-08-09 KR KR1020087012026A patent/KR100885601B1/ko not_active Expired - Fee Related
- 2001-08-09 EP EP07075711A patent/EP1994940B1/de not_active Expired - Lifetime
- 2001-08-09 MX MXPA03001237A patent/MXPA03001237A/es active IP Right Grant
- 2001-08-09 CA CA2418531A patent/CA2418531C/en not_active Expired - Fee Related
- 2001-08-09 AU AU9175501A patent/AU9175501A/xx active Pending
- 2001-08-09 CN CNB018170021A patent/CN100558744C/zh not_active Expired - Fee Related
- 2001-08-09 AT AT07075711T patent/ATE555802T1/de active
- 2001-08-09 CA CA2804958A patent/CA2804958A1/en not_active Abandoned
- 2001-08-09 AT AT01971896T patent/ATE377426T1/de not_active IP Right Cessation
- 2001-08-09 CZ CZ2003-406A patent/CZ304572B6/cs not_active IP Right Cessation
- 2001-08-09 NZ NZ524000A patent/NZ524000A/en not_active IP Right Cessation
- 2001-08-09 RU RU2003106435/14A patent/RU2282460C2/ru not_active IP Right Cessation
- 2001-08-09 JP JP2002519493A patent/JP5105687B2/ja not_active Expired - Fee Related
- 2001-08-09 NZ NZ542370A patent/NZ542370A/en not_active IP Right Cessation
2003
- 2003-01-29 IL IL154170A patent/IL154170A/en not_active IP Right Cessation
2006
- 2006-08-17 AU AU2006203640A patent/AU2006203640B2/en not_active Ceased
2009
- 2009-03-12 IL IL197584A patent/IL197584A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU2006203640B2 (en)	2009-01-08
NZ542370A (en)	2006-09-29
CZ304572B6 (cs)	2014-07-16
CA2804958A1 (en)	2002-02-21
BR0113189A (pt)	2003-09-16
AU2001291755B2 (en)	2006-05-18
WO2002014356A3 (de)	2003-01-30
WO2002014356A2 (de)	2002-02-21
CN1636014A (zh)	2005-07-06
IL154170A0 (en)	2003-07-31
IL154170A (en)	2009-09-22
JP5105687B2 (ja)	2012-12-26
EP1994940B1 (de)	2012-05-02
MXPA03001237A (es)	2004-09-10
CA2418531C (en)	2013-10-01
AU9175501A (en)	2002-02-25
IL197584A (en)	2013-07-31
JP2004506652A (ja)	2004-03-04
HUP0300740A2 (hu)	2003-09-29
CZ2003406A3 (cs)	2003-06-18
DE60131286D1 (de)	2007-12-20
KR100887463B1 (ko)	2009-03-10
RU2282460C2 (ru)	2006-08-27
EP1994940A1 (de)	2008-11-26
KR100885601B1 (ko)	2009-02-24
DE60131286T2 (de)	2008-08-28
BRPI0113189B1 (pt)	2015-07-07
ATE555802T1 (de)	2012-05-15
KR20030034134A (ko)	2003-05-01
CN100558744C (zh)	2009-11-11
KR20080048560A (ko)	2008-06-02
IL197584A0 (en)	2011-07-31
PL364248A1 (en)	2004-12-13
AU2006203640A1 (en)	2006-09-14
HUP0300740A3 (en)	2010-03-29
US7078376B1 (en)	2006-07-18
CA2418531A1 (en)	2002-02-21
NZ524000A (en)	2007-06-29
EP1317276B1 (de)	2007-11-07
EP1317276A2 (de)	2003-06-11

Legal Events

Date

Code

Title

Description

2008-05-15

UEP

Publication of translation of european patent specification

Ref document number: 1317276

Country of ref document: EP

2011-05-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE60131286D1 (de)	2007-12-20	Therapeutische verwendung eines rekombinanten erythropoietins omega mit hoher aktivität und verminderten nebenwirkungen
RU2003106435A (ru)	2004-07-10	Терапевтические способы для лечения субъектов рекомбинантным эритропоэтином, имеющим высокую активность и уменьшенные побочные действия
AU766216B2 (en)	2003-10-09	Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
Ceaglio et al.	2008	Novel long-lasting interferon alpha derivatives designed by glycoengineering
Morreale et al.	2004	Clinical and economic comparison of epoetin alfa and darbepoetin alfa
US20070196375A1 (en)	2007-08-23	Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
US20130022540A1 (en)	2013-01-24	Methods to facilitate transmission of large molecules across the blood-brain, blood-eye, and blood-nerve barriers
Amital et al.	2003	Fibrosis regression induced by intravenous gammaglobulin treatment
KR0137361B1 (ko)	1998-04-25	Gm-csf를 포함하는 백혈구 기능장애 치료조성물
JP2009524612A (ja)	2009-07-02	多発性硬化症を治療及び／又は予防するための方法、ならびに多発性硬化症の間欠的治療用及び／又は間欠的予防用の薬剤を製造するためのエリスロポエチンの使用
US20200131240A1 (en)	2020-04-30	Use of il-12 to generate endogenous erythropoietin
RU2002102025A (ru)	2004-03-10	Способ лечения больных хроническим вирусным гепатитом C
CN106821633A (zh)	2017-06-13	一种用于肿瘤内科的护理床
NZ532763A (en)	2008-01-31	Method of administering a thymosin alpha 1 peptide
US6967191B2 (en)	2005-11-22	System for treating eye and nerve diseases in diabetic and non-diabetic patients
KR102579654B1 (ko)	2023-09-18	지속형 epo 제제를 이용한 빈혈 치료 방법
RU2348417C1 (ru)	2009-03-10	Способ коррекции нейроэндокринного и иммунного состояния организма (варианты)
RU2196576C1 (ru)	2003-01-20	Способ лечения больных геморрагической лихорадкой с почечным синдромом (глпс)
Sharvadze et al.	2006	Ifn/Rbv treatment induced anemia and its correction with epoetin alpha in patients with hepatitis C
Liniger et al.	1998	Tumoral calcinosis and atypical juvenile dermatomyositis: case report
RU2285533C2 (ru)	2006-10-20	Способ введения хлористого кальция
Matthews et al.	1987	Iatrogenic superior vena cava syndrome treated with streptokinase
Xu	0	Human Recombinant Erythropoietin Treatment
Pajtasz-Piasecka et al.	2001	The effects of peritumoral therapeutic vaccination with IL-2-secreting cells on growth of MC38 colon tumours in mice, local NO production and sentinel lymph node cells activation
RU2023133582A (ru)	2024-01-15	Терапевтическая фармацевтическая композиция для лечения опухолей костей и мягких тканей